Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.
The CD30-targeting Ab-drug conjugate brentuximab vedotin (SGN-35) was recently approved for the treatment of relapsed Hodgkin lymphoma and anaplastic large-cell lymphoma by the Food and Drug Administration. In the present study, we report the experience of the German Hodgkin Study Group with brentuximab vedotin as single agent in 45 patients with refractory or relapsed CD30(+) Hodgkin lymphoma who were treated either in a named patient program (n = 34) or in the context of a safety study associated with the registration program of this drug. In these very heavily pretreated patients, an objective response rate of 60%, including 22% complete remissions, could be documented. The median duration of response was 8 months. This retrospective analysis supports the previously reported excellent therapeutic efficacy of brentuximab vedotin in heavily pretreated CD30(+) malignancies.
First Department of Internal Medicine, University Hospital of Cologne, Kerpener Strasse 62, Cologne, Germany.
Achim
A
Rothe
Stephanie
S
Sasse
Helen
H
Goergen
Dennis A
DA
Eichenauer
Andreas
A
Lohri
Ulrich
U
Jäger
Christopher
C
Bangard
Boris
B
Böll
Michael
M
von Bergwelt Baildon
Sebastian
S
Theurich
Peter
P
Borchmann
Andreas
A
Engert
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D017321:Clinical Trials, Phase I as Topic; D018572:Disease-Free Survival; D005260:Female; D005858:Germany; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D017730:Ki-1 Antigen / Q000378:metabolism*; D008297:Male; D012008:Recurrence; D012189:Retrospective Studies
D000970:Antineoplastic Agents; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin